At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 70 enrolled
Drug / intervention
1.3% Liposomal Bupivacaine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Novel Application of Exparel for Postoperative Pain Management in Shoulder Arthroplasty and Humerus Fracture Fixation
In Brief
A Phase 4 clinical trial evaluating 1.3% Liposomal Bupivacaine and 0.125% Bupivacaine for Fracture of Shoulder and Upper Arm. Completed, enrolled 70 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the effect of liposomal Bupivacaine infiltration into the shoulder to continues nerve block with Bupivacaine on postoperative pain control and functional outcomes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFracture of Shoulder and Upper Arm
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJun 2015
First PostedJun 2015
Primary CompletionMay 2017
TodayJul 2026
First PostedJun 15, 2015
Enrollment StartJun 1, 2015
Primary CompletionMay 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 11.0 years ago
Interventions
1.3% Liposomal Bupivacainedrug
local tissue infiltration of Liposomal Bupivacaine during surgery
0.125% Bupivacainedrug
Continues nerve block with Bupivacaine during surgery and postoperatively